Budesonide, a locally acting steroid taken by mouth, is the cornerstone of microscopic colitis treatment and the only therapy backed by multiple randomized trials. In the best studied trials, roughly 80–87% of patients reached remission within about eight weeks on budesonide, compared with 12–60% on placebo. But the treatment picture is more layered than “take budesonide and you’re done.” The condition relapses frequently once the drug is stopped, certain everyday medications can be driving it in the first place, and a meaningful minority of patients need entirely different approaches.
Removing Medication Triggers First
Before adding a new drug, the first treatment step is checking whether an existing one is causing or worsening the problem. Several common medication classes are linked to a substantially higher risk of developing microscopic colitis. A systematic review and meta-analysis found that proton pump inhibitors (the acid-suppressing drugs many people take for reflux) roughly doubled to tripled the odds, while SSRIs (a widely prescribed class of antidepressants), NSAIDs (over-the-counter painkillers like ibuprofen and naproxen), and statins each carried meaningfully elevated risk as well.1PubMed Central. Are Drugs Associated with Microscopic Colitis? A Systematic Review and Meta-Analysis A separate case-control study found that current use of PPIs was associated with more than three times the odds of microscopic colitis, and that using NSAIDs and PPIs together pushed the risk even higher.2PubMed. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors
If you’ve been on one of these drugs and then developed chronic watery diarrhea, stopping or switching the medication (with your prescriber’s help) sometimes resolves symptoms entirely, making further treatment unnecessary. This is not always possible; some people genuinely need their PPI or SSRI. But the conversation about culprit medications should happen before committing to budesonide, because it can spare you from long-term immunosuppressive therapy altogether.
Budesonide for Induction
When medication withdrawal alone doesn’t do the trick, budesonide is the standard first-line drug. It works locally in the gut and gets mostly broken down in the liver before reaching the rest of the body, which limits (but doesn’t eliminate) typical steroid side effects. In a well-known randomized trial of collagenous colitis, the remission rate was about 87% in the budesonide group versus roughly 14% with placebo, and histologic improvement followed a similar pattern.3PubMed. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial A later head-to-head trial also showed budesonide outperforming mesalamine, a milder anti-inflammatory sometimes tried first: 80% remission with budesonide versus 44% with mesalamine at eight weeks.4PubMed. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis Across multiple studies, budesonide has proven effective for both main subtypes of the disease, collagenous colitis and lymphocytic colitis, and is generally well tolerated in the short term.5PubMed Central. Use of budesonide in the treatment of microscopic colitis
A typical induction course starts at 9 mg daily for six to eight weeks, then tapers down. Most people feel noticeably better within the first two weeks. The drug doesn’t cure the underlying process, but it suppresses the immune-driven inflammation responsible for the watery diarrhea.
The Relapse Problem
Here is where treatment gets complicated: microscopic colitis loves to come back once budesonide is stopped. In a population-based study, about 63% of patients who initially responded to budesonide relapsed after discontinuing it, with a median time to relapse of roughly three months.6PubMed Central. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile from a Population-Based Study A randomized 12-month trial painted a similar picture: about 61% of patients stayed in remission on low-dose budesonide maintenance, compared with only about 17% on placebo, but after stopping the drug at the end of the trial, over 80% relapsed within a median of 40 days.7Gut. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial Clinical practice series have documented similar relapse rates of around 50–80% when budesonide is tapered or stopped.8Digestive and Liver Disease. Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment
The practical consequence is that many patients end up on long-term, low-dose budesonide maintenance, often at 3 mg daily or every other day. In the population-based study mentioned above, every patient on maintenance therapy responded (nearly all completely), and none relapsed while still taking it.9PubMed Central. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile from a Population-Based Study The downside is that even low-dose budesonide is still a steroid, and years of use can raise concerns about bone thinning, blood sugar changes, and adrenal suppression. Doctors typically aim for the lowest dose that keeps symptoms at bay and periodically attempt to taper off.
Milder Options Worth Trying
Not everyone needs budesonide. For milder symptoms, or for patients who prefer to avoid steroids, a few gentler options exist.
Bismuth subsalicylate (the active ingredient in Pepto-Bismol) has surprisingly decent evidence behind it. In one study of 94 patients treated with bismuth subsalicylate, about 57% achieved complete symptom resolution and another 21% had partial improvement. Among those who relapsed after stopping, over 80% responded again when they restarted it.10American Journal of Gastroenterology. Outcomes of Bismuth Subsalicylate Treatment in Patients With Microscopic Colitis An earlier open-label trial found that an eight-week course was safe and well tolerated.11PubMed. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis The dose used in trials is higher than what you’d take for an upset stomach (typically nine tablets a day, divided into three doses), and it needs to be taken consistently for weeks, not just as needed.
Cholestyramine, a bile acid binder, targets a specific mechanism. A substantial fraction of people with microscopic colitis also have bile acid malabsorption, meaning bile acids that should be reabsorbed in the small intestine instead spill into the colon and trigger watery diarrhea. One study found that roughly 43% of microscopic colitis patients had bile acid malabsorption, with the rate reaching 60% in those with the lymphocytic subtype. In patients who tested positive, cholestyramine induced remission in the vast majority.12PubMed. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea The catch is that cholestyramine is a gritty powder that many people find unpleasant to drink, and it can interfere with the absorption of other medications. It works best for the subset of patients who have bile acid malabsorption as a co-driver, not as a universal fix.
Loperamide (Imodium) is sometimes used alongside other treatments for basic symptom relief. It doesn’t address the underlying inflammation, but it can reduce stool frequency and urgency enough to make daily life manageable while other therapies kick in.
When Budesonide Isn’t Enough
A small but real fraction of patients either don’t respond to budesonide, can’t tolerate it, or relapse the moment it’s tapered despite multiple attempts. This “refractory” or “steroid-dependent” group faces harder choices.
Immunomodulators like azathioprine, mercaptopurine, and methotrexate are sometimes tried in this setting. The evidence is thin and the response rates are uneven. In the largest case series on the topic, thiopurines (azathioprine and mercaptopurine) produced complete responses in about 43% and partial responses in another 22%, but over a third of patients had to stop due to side effects. Methotrexate fared somewhat better, with complete responses in about 58%, though the number of patients studied was small.13PubMed. Immune modulator therapy for microscopic colitis in a case series of 73 patients A review of the broader literature characterized immunomodulator response rates as ranging from 0% to 56%.14PubMed Central. Microscopic colitis: A review of etiology, treatment and refractory disease
Biologic therapies are the newest frontier. Vedolizumab, which targets immune cells that home to the gut, has shown the most promising results in steroid-refractory patients. A pooled analysis of available studies reported a clinical remission rate of about 64% with vedolizumab, compared with about 58% for infliximab and roughly 39% for adalimumab. Vedolizumab also had the lowest rate of side effects requiring discontinuation, at about 12%, versus roughly a third for infliximab.15PubMed. Efficacy and Safety of Vedolizumab and Tumor Necrosis Factor Inhibitors in the Treatment of Steroid-refractory Microscopic Colitis: A Systematic Review and Meta-analysis An international case series of 11 heavily pretreated patients found that about half achieved remission after three vedolizumab infusions, with some maintaining it for over a year.16PubMed. Vedolizumab in Refractory Microscopic Colitis: An International Case Series These are encouraging numbers, but the total number of patients studied in all biologic trials combined is still small, so the evidence base remains limited compared with the budesonide data.
Why It Gets Mistaken for IBS
A frustrating feature of microscopic colitis is how long people can go without a correct diagnosis. The primary symptom, chronic watery diarrhea without visible blood, looks almost identical to diarrhea-predominant irritable bowel syndrome. The colon appears completely normal during colonoscopy unless biopsies are taken, which is how the disease got its name: the abnormalities are only visible under a microscope.17PubMed Central. Microscopic colitis – a missed diagnosis in diarrhea-predominant irritable bowel syndrome In routine clinical settings, there is a recognized risk of the disease being mislabeled as IBS or overlooked entirely, particularly in older adults.18PubMed Central. Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care
This matters for treatment because an IBS label typically leads to dietary advice and antispasmodics, not budesonide. If you’ve been told you have IBS but your main symptom is persistent watery (not alternating) diarrhea, especially if you’re over 50 or female, it’s worth asking whether biopsies were actually taken during your colonoscopy. The distinction between the two subtypes, collagenous colitis and lymphocytic colitis, also depends entirely on what the pathologist sees: a thickened collagen band beneath the surface lining in collagenous colitis, versus a heavy infiltration of lymphocytes (a type of immune cell) in the surface lining in lymphocytic colitis.19Human Pathology. Lymphocytic (“microscopic”) colitis: A comparative histopathologic study with particular reference to collagenous colitis Treatment overlaps heavily between the two, but bile acid malabsorption is more common in the lymphocytic form, which can guide whether a bile acid binder is worth trying.
Smoking and Microscopic Colitis
Unlike ulcerative colitis, where smoking appears somewhat protective, smoking is a clear risk factor for microscopic colitis. Data from two large prospective cohort studies of U.S. women found that current smokers had roughly two and a half times the risk compared with nonsmokers. The association was even stronger for the collagenous subtype, where current smokers had nearly four times the risk. Past smokers carried a smaller but still elevated risk, and the more pack-years accumulated, the higher the risk climbed. Encouragingly, risk decreased after quitting.20PubMed Central. Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women
Quitting smoking won’t treat active disease the way budesonide does, but for current smokers with microscopic colitis it’s one of the few modifiable risk factors in play. Some clinicians suspect smoking may also make the disease harder to control with medication, though the data on that specific question is less definitive.
The Autoimmune Connection
Microscopic colitis doesn’t exist in isolation. About 22% of patients in a large Danish case-control study had at least one autoimmune disease, compared with 11% of matched controls. The strongest association was with celiac disease, where the odds ratio exceeded 10, meaning people with celiac disease were roughly ten times more likely to also have microscopic colitis. Associations also appeared with Crohn’s disease, ulcerative colitis, thyroid disorders, and several connective tissue diseases.21PubMed. Autoimmune diseases in microscopic colitis: A Danish nationwide case-control study A separate meta-analysis confirmed that about 6% of microscopic colitis patients also have celiac disease, and about 6% of celiac disease patients have microscopic colitis.22PubMed Central. The association between microscopic colitis and celiac disease: a systematic review and meta-analysis
This overlap matters for treatment planning in two ways. First, if you have microscopic colitis and haven’t been screened for celiac disease, it’s worth doing, because an undiagnosed gluten sensitivity could be contributing to your diarrhea and might respond to a gluten-free diet. Second, the clustering of autoimmune conditions suggests that microscopic colitis is fundamentally an immune-mediated disease, which helps explain why it responds to immune-suppressing drugs and why it tends to be chronic rather than self-limiting.
Quality of Life and Fatigue
One thing that often surprises patients is how much microscopic colitis can affect life beyond the bathroom. The diarrhea itself is disruptive, but many patients also report significant fatigue that persists even when bowel symptoms are partially controlled. A study examining fatigue in microscopic colitis patients found strong correlations between fatigue severity and measures of anxiety, depression, and reduced quality of life.23PubMed Central. Fatigue and its associated factors in microscopic colitis The diarrhea in microscopic colitis results at least partly from impaired sodium absorption and barrier defects in the colon lining, which can contribute to dehydration and electrolyte imbalances that compound the exhaustion.24PubMed. Ion transport and barrier function are disturbed in microscopic colitis
Effective treatment of the underlying colitis generally helps with fatigue, but some patients find that fatigue lingers even after diarrhea resolves. This may partly reflect the autoimmune milieu that drives the disease. Discussing persistent fatigue with your doctor is worth doing rather than assuming it’s unrelated.
Long-Term Outlook and Cancer Risk
One of the most reassuring aspects of microscopic colitis is that it does not appear to increase the risk of colon cancer or other cancers. This sets it apart from the major forms of inflammatory bowel disease, where longstanding inflammation raises colorectal cancer risk. A retrospective cohort study comparing microscopic colitis patients with colonoscopy controls and the general U.S. population found no increased risk of colorectal or extracolonic cancers.25PubMed Central. Cancer risk in microscopic colitis: a retrospective cohort study Another study actually found lower rates of colorectal cancer and adenomas in microscopic colitis patients compared with controls.26PubMed. Decreased colorectal cancer and adenoma risk in patients with microscopic colitis A population-based cohort that followed patients long-term similarly found no excess cancer, and none of the deaths observed during follow-up were attributable to microscopic colitis itself.27PubMed Central. Long-Term Natural History of Microscopic Colitis: A Population-Based Cohort
The disease can be chronic and annoying, and some patients deal with it for years or decades. But it is not dangerous in the way that Crohn’s disease or ulcerative colitis can be, and it does not shorten life expectancy based on available evidence. For many patients, the right treatment strategy (whether that’s medication withdrawal, budesonide, or one of the alternatives) eventually brings the disease to a manageable place.
The Microbiome Question
Research into the gut microbiome’s role in microscopic colitis is still in early stages. Studies have detected differences in the microbial composition of patients with microscopic colitis compared with healthy controls, and there has been discussion of whether targeted probiotics or even fecal microbiota transplantation could eventually play a therapeutic role.28PubMed Central. Dysbiosis of Gut Microbiota in Microscopic Colitis: Diagnostic and Therapeutic Implications At this point, though, there are no rigorous trials showing that any specific probiotic strain reliably improves microscopic colitis outcomes. Barrier function and microbiome changes are being studied together as potential new avenues for treatment and patient stratification.29PubMed Central. Microscopic colitis-microbiome, barrier function and associated diseases If a probiotic helps your symptoms, there’s little harm in continuing it, but it should not replace evidence-based therapies like budesonide in anyone with active disease.